South Korea's HF to issue 500 mln euro covered bond this year Its strong credit rating and wide investor base likely to lure investors
Translated by Soin Kim 공개 2021-03-22 08:14:20
이 기사는 2021년 03월 22일 08시00분 thebell에 표출된 기사입니다
Korea Housing Finance Corporation (HF), the South Korean public financial company that provides housing loans, has started a process to sell euro-denominated covered bonds this year.The HF has invited major foreign securities firms to pitch for a lead manager role to issue Korean paper covered bonds. Korean paper refers to foreign currency debt issued by South Korean entities abroad. The corporation plans to receive proposals by March 23 and start its selection process.
The HF plans to issue around 500 million euros (674 billion won) worth of covered bonds in the second half of this year. Covered bonds worth $500 million will mature in October.
The HF has sold covered bonds worth 500 million euros in the European market every year since its first 500 million euro offering of a covered bond in 2018. The corporation raised a combined 1.5 billion euros last year through two rounds of covered bond offerings.
Foreign currency-denominated bonds have become less attractive this year as the dollar-denominated bond market has stabilized due to low interest rates. Hana Bank, which tried to sell euro-denominated covered bonds earlier this year for the first time, had to bear higher funding cost than Woori Bank, which sold dollar-denominated bonds around the same time.
The fact that the HF has put continuous effort to widen the investor base in the European bond market and its AAA-rated covered bond are expected to help attract investors. (Reporting by Hye-rim Pi)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- [i-point]'자가면역질환 신약' 이노보테라퓨틱스, 미국 임상 1상 '성공적'
- [i-point]폴라리스오피스, 엔비디아 ‘커넥트’ 공식 파트너 선정
- [i-point]신성이엔지, 한국종합기술·다스코와 연료전지 발전사업 협약
- [i-point]신테카바이오, 'PEGS 보스턴 2025' 참가
- [AACR 2025]첫 구두발표 진씨커, 경쟁사 넘보는 '유전자가위 액체생검'
- [AACR 2025]이뮨온시아 'CD47' 안전성 굳히기 "경쟁약과 다르다"
- [AACR 2025]항암 신약 항체 대신 '페라틴', 셀레메디 플랫폼 데뷔전
- [AACR 2025]근거 쌓는 '루닛 스코프' 빅파마 공동연구 쇼케이스
- [변곡점 선 콜마비앤에이치]변화의 마지막 카드, 경영진 교체 '강수' 두나
- [변곡점 선 콜마비앤에이치]속절없는 주가 하락 '트리거', 주가 부양 의지 없었나